loading...| Preferred Name |
testolactone |
|
| Synonyms |
17alpha-oxo-D-homo-1,4-androstadiene-3,17-dione |
|
| Definitions |
A progesterone derivative with antineoplastic activity. Testolactone inhibits steroid aromatase, thereby preventing the formation of estrogen from adrenal androstenedione and reducing endogenous estrogen levels. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C2301" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C2301" NCI Thesaurus) |
|
| ID |
http://purl.bioontology.org/ontology/PDQ/CDR0000042916 |
|
| altLabel |
17alpha-oxo-D-homo-1,4-androstadiene-3,17-dione delta-1-testololactone 13-hydroxy-3-0x0-13,17-secoandrosta-1,4-dien-17-oic acid delta-lactone TL therapeutic testolactone Teslac D-homo-17a-oxaandrosta-1,4-diene-3,17-dione 1-dehydrotestololactone 1,2,3,4,4a,4b,7,9,10,10a-decahydro-2-hydroxy-2,4b-dimethyl-7-oxo-1-phenanthrenepropionic acid delta-lactone Fludestrin SQ-9538 |
|
| CAS Registry |
968-93-4 |
|
| cui |
C0039600 C0740162 C1527154 C1527155 |
|
| definition |
A progesterone derivative with antineoplastic activity. Testolactone inhibits steroid aromatase, thereby preventing the formation of estrogen from adrenal androstenedione and reducing endogenous estrogen levels. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C2301" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C2301" NCI Thesaurus) |
|
| IND Code |
920 |
|
| Legacy PDQ ID |
675 |
|
| LT |
TRD |
|
| NCI ID |
C2301 |
|
| notation |
CDR0000042916 |
|
| NSC Code |
23759 |
|
| ORIG STY |
Drug/agent |
|
| prefLabel |
testolactone |
|
| tui |
T125 T109 T121 |